Analysts Expect Corium International Inc (CORI) Will Announce Quarterly Sales of $7.82 Million

Share on StockTwits

Analysts expect Corium International Inc (NASDAQ:CORI) to announce $7.82 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Corium International’s earnings, with the highest sales estimate coming in at $7.83 million and the lowest estimate coming in at $7.81 million. Corium International posted sales of $9.44 million during the same quarter last year, which suggests a negative year over year growth rate of 17.2%. The business is expected to issue its next quarterly earnings report on Thursday, November 15th.

On average, analysts expect that Corium International will report full-year sales of $34.51 million for the current financial year, with estimates ranging from $34.15 million to $34.86 million. For the next year, analysts anticipate that the business will report sales of $38.10 million per share, with estimates ranging from $37.76 million to $38.44 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow Corium International.

Corium International (NASDAQ:CORI) last issued its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04. Corium International had a negative return on equity of 276.89% and a negative net margin of 155.21%. The firm had revenue of $7.67 million during the quarter, compared to analyst estimates of $6.72 million.

CORI has been the topic of several research reports. Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 target price on shares of Corium International in a research report on Friday, August 10th. Zacks Investment Research raised Corium International from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Corium International in a research report on Monday, August 13th. BidaskClub raised Corium International from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 13th. Finally, ValuEngine downgraded Corium International from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $12.80.

Shares of NASDAQ CORI traded down $0.07 during mid-day trading on Monday, hitting $9.72. The stock had a trading volume of 3,999 shares, compared to its average volume of 271,672. The company has a debt-to-equity ratio of 2.83, a current ratio of 7.61 and a quick ratio of 7.47. Corium International has a twelve month low of $7.17 and a twelve month high of $13.93. The company has a market cap of $353.80 million, a price-to-earnings ratio of -5.97 and a beta of 1.60.

In related news, insider Joseph J. Sarret sold 3,565 shares of the company’s stock in a transaction on Friday, August 17th. The stock was sold at an average price of $9.01, for a total value of $32,120.65. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Parminder Singh sold 3,133 shares of the company’s stock in a transaction on Friday, August 17th. The shares were sold at an average price of $9.01, for a total value of $28,228.33. The disclosure for this sale can be found here. Over the last three months, insiders sold 119,965 shares of company stock worth $1,060,275. 30.80% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC acquired a new stake in Corium International during the 4th quarter worth about $123,000. DekaBank Deutsche Girozentrale acquired a new stake in Corium International during the 1st quarter worth about $167,000. Engineers Gate Manager LP acquired a new stake in Corium International during the 2nd quarter worth about $215,000. Alps Advisors Inc. acquired a new stake in Corium International during the 2nd quarter worth about $420,000. Finally, Citadel Advisors LLC acquired a new stake in Corium International during the 1st quarter worth about $455,000.

Corium International Company Profile

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Recommended Story: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Corium International (CORI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply